AUTH:"Leav B" - Search results

COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials.

Sherman AC, Tuan J, Cantos VD, Adeyiga O, Mahoney S, Ortega-Villa AM, Tillman A, Whitaker J, Woodward Davis AS, Leav B, Hirsch I, Sadoff J, Dunkle LM, Gilbert PB, Janes HE, Kublin JG, Goepfert PA, Kotloff K, Rouphael N, [...] Gay CL

Clin Infect Dis, 79(2):364-374, 01 Aug 2024

Cited by: 0 articles | PMID: 38598658

Add to export list

Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study

Garrett N, Reddy T, Yende-Zuma N, Takalani A, Woeber K, Bodenstein A, Jonas P, Engelbrecht I, Jassat W, Moultrie H, Bradshaw D, Seocharan I, Odhiambo J, Khuto K, Richardson SI, Omondi MA, Nesamari R, Keeton RS, Riou C, [...] the SHERPA study team

medRxiv, 11 Jun 2024

Cited by: 0 articles | PPR: PPR865311

Add to export list Preprint

SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.

Fisher LH, Kee JJ, Liu A, Espinosa CM, Randhawa AK, Ludwig J, Magaret CA, Robinson ST, Gilbert PB, Hyrien O, Kublin JG, Rouphael N, Falsey AR, Sobieszczyk ME, El Sahly HM, Grinsztejn B, Gray GE, Kotloff KL, Gay CL, [...] COVID-19 Prevention Network (CoVPN)

JAMA Netw Open, 7(5):e2412835, 01 May 2024

Cited by: 1 article | PMID: 38780941 | PMCID: PMC11117088

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.

Naficy A, Kuxhausen A, Seifert H, Hastie A, Leav B, Miller J, Anteyi K, Mwakingwe-Omari A

Hum Vaccin Immunother, 20(1):2327736, 21 Mar 2024

Cited by: 0 articles | PMID: 38513689 | PMCID: PMC10962584

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.

Dukes CW, Potez M, Lancet J, Kuter BJ, Whiting J, Mo Q, Leav B, Wang H, Vanas JS, Cubitt CL, Isaacs-Soriano K, Kennedy K, Rathwell J, Diaz Cobo J, O'Nan W, Sirak B, Dong N, Tan E, Hwu P, [...] Pilon-Thomas S

Vaccines (Basel), 12(1):13, 22 Dec 2023

Cited by: 0 articles | PMID: 38250826 | PMCID: PMC10818923

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.

Narayanasamy S, Curtis LH, Hernandez AF, Woods CW, Moody MA, Sulkowski M, Turbett SE, Baden LR, Gulick RM, Pau AK, Adam SJ, Marks P, Stockbridge NL, Dobbins JR, Krofah E, Leav B, Pang P, Roessig L, Vedin O, [...] Naggie S

Clin Infect Dis, 77(12):1635-1643, 01 Dec 2023

Cited by: 3 articles | PMID: 37435958 | PMCID: PMC10724451

Add to export list Review

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial.

Naficy A, Kuxhausen A, Pirrotta P, Leav B, Miller J, Anteyi K, Danier J, Breuer T, Mwakingwe-Omari A

Clin Infect Dis, 77(9):1238-1246, 01 Nov 2023

Cited by: 2 articles | PMID: 37335963 | PMCID: PMC10640691

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial.

Hejazi NS, Shen X, Carpp LN, Benkeser D, Follmann D, Janes HE, Baden LR, El Sahly HM, Deng W, Zhou H, Leav B, Montefiori DC, Gilbert PB

Int J Infect Dis, 137:28-39, 25 Oct 2023

Cited by: 3 articles | PMID: 37820782 | PMCID: PMC10841741

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Risk of COVID-19 after natural infection or vaccination.

Rick AM, Laurens MB, Huang Y, Yu C, Martin TCS, Rodriguez CA, Rostad CA, Maboa RM, Baden LR, El Sahly HM, Grinsztejn B, Gray GE, Gay CL, Gilbert PB, Janes HE, Kublin JG, Huang Y, Leav B, Hirsch I, [...] NIAID-funded COVID-19 Prevention Network (CoVPN)

EBioMedicine, 96:104799, 20 Sep 2023

Cited by: 2 articles | PMID: 37738833 | PMCID: PMC10518569

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.

Giuliano A, Kuter B, Pilon-Thomas S, Whiting J, Mo Q, Leav B, Sirak B, Cubitt C, Dukes C, Isaacs-Soriano K, Kennedy K, Ball S, Dong N, Jain A, Hwu P, Lancet J

Cancer Commun (Lond), 43(7):749-764, 28 Jun 2023

Cited by: 5 articles | PMID: 37377402 | PMCID: PMC10354405

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.

Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, Osman R, Babu TM, Robinson ST, Gilbert PB, Follmann D, Janes H, Kublin JG, Baden LR, Goepfert P, Gray GE, Grinsztejn B, Kotloff KL, Gay CL, [...] COVID-19 Prevention Network (CoVPN)

JAMA Netw Open, 6(7):e2323349, 03 Jul 2023

Cited by: 8 articles | PMID: 37440227 | PMCID: PMC10346130

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.

Turley CB, Tables L, Fuller T, Sanders LJ, Scott H, Moodley A, Woodward Davis A, Leav B, Miller J, Schoemaker K, Vandebosch A, Sadoff J, Woo W, Cho I, Dunkle LM, Li S, van der Laan L, Gilbert PB, Follmann D, [...] COVID-19 Prevention Network CoVPN

Vaccine, 41(33):4899-4906, 23 Jun 2023

Cited by: 4 articles | PMID: 37385888 | PMCID: PMC10288314

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS

Naficy A, Pirrotta P, Kuxhausen A, Miller J, Leav B, Mwakingwe-Omari A

Int J Infect Dis, 130:S55-S56, 01 May 2023

Cited by: 0 articles | PMCID: PMC10186933

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Risk of COVID-19 after Natural Infection or Vaccination

Rick A, Laurens MB, Huang Y, Yu C, Martin TCS, Rodriguez CA, Rostad C, Maboa RM, Baden L, Sahly HME, Grinsztejn B, Gray G, Gay CL, Gilbert PB, Janes HE, Kublin JG, Huang Y, Leav B, Hirsch I, [...] Kotloff KL

SSRN, 01 May 2023

Cited by: 0 articles | PPR: PPR652976

Add to export list Preprint

No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a COVID-19 mRNA-1273 booster vaccine in adults aged 50 years and older: A randomized trial

Naficy A, Kuxhausen A, Pirrotta P, Leav B, Miller J, Anteyi K, Adams MS, Danier J, Breuer T, Mwakingwe-Omari A

medRxiv, 12 Mar 2023

Cited by: 0 articles | PPR: PPR648813

Add to export list Preprint

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.

Essink B, Chu L, Seger W, Barranco E, Le Cam N, Bennett H, Faughnan V, Pajon R, Paila YD, Bollman B, Wang S, Dooley J, Kalidindi S, Leav B

Lancet Infect Dis, 23(5):621-633, 19 Jan 2023

Cited by: 26 articles | PMID: 36682364

Add to export list

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.

Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, Chen X, Chang Y, Zhou H, Montefiori D, Edwards DK, Girard B, Pajon R, Dutko FJ, Leav B, Walsh SR, Baden LR, Miller JM, Das R

Nat Med, 28(11):2388-2397, 06 Oct 2022

Cited by: 77 articles | PMID: 36202997 | PMCID: PMC9671805

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial.

El Sahly HM, Baden LR, Essink B, Montefiori D, McDermont A, Rupp R, Lewis M, Swaminathan S, Griffin C, Fragoso V, Miller VE, Girard B, Paila YD, Deng W, Tomassini JE, Paris R, Schödel F, Das R, August A, [...] Coronavirus Efficacy (COVE) Study Group

J Infect Dis, 226(10):1731-1742, 01 Nov 2022

Cited by: 9 articles | PMID: 35535503 | PMCID: PMC9213865

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).

Leav B, Straus W, White P, Leav A, Gaines T, Maggiacomo G, Kim D, Smith ER, Gurwith M, Chen RT, Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO ex-V3SWG

Vaccine, 40(35):5275-5293, 09 Jun 2022

Cited by: 2 articles | PMID: 35753841 | PMCID: PMC9181264

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine

Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, Chen X, Chang Y, Zhou H, Montefiori D, Edwards DK, Girard B, Pajon R, Leav B, Walsh SR, Baden LR, Miller JM, Das R

Research Square, 15 Apr 2022

Cited by: 0 articles | PPR: PPR482496

Add to export list Preprint v1

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim Analysis

Anderson E, Jackson L, Rouphael N, Widge A, Montefiori D, Doria-Rose N, Suthar M, Cohen K, O'Connell S, Makowski M, Makhene M, Buchanan W, Spearman P, Creech CB, O'Dell S, Schmidt S, Leav B, Bennett H, Pajon R, [...] Roberts P

Research Square, 03 May 2022

Cited by: 0 articles | PPR: PPR487706

Add to export list Preprint v1

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent Vaccines

Anderson EJ, Jackson LA, Rouphael NG, Widge AT, Montefiori D, Doria-Rose NA, Suthar M, Cohen KW, O’Connell S, Makowski M, Makhene M, Buchanan W, Spearman P, Creech CB, O’Dell S, Schmidt SD, Leav B, Bennett H, Pajon R, [...] Roberts PC

Research Square, 26 Apr 2022

Cited by: 0 articles | PPR: PPR485846

Add to export list Preprint v1

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.

Pajon R, Paila YD, Girard B, Dixon G, Kacena K, Baden LR, El Sahly HM, Essink B, Mullane KM, Frank I, Denhan D, Kerwin E, Zhao X, Ding B, Deng W, Tomassini JE, Zhou H, Leav B, Schödel F, COVE Trial Consortium

Nat Med, 28(4):823-830, 10 Feb 2022

Cited by: 26 articles | PMID: 35145311 | PMCID: PMC9018421

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.

Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y, Carfi A, Edwards DK, Oestreicher J, Legault H, Dutko FJ, Girard B, Pajon R, Miller JM, Das R, Leav B, McPhee R

Nat Med, 28(5):1042-1049, 03 Mar 2022

Cited by: 53 articles | PMID: 35241844 | PMCID: PMC9117133

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Chalkias S, Schwartz H, Nestorova B, Feng J, Chang Y, Zhou H, Dutko FJ, Edwards DK, Montefiori D, Pajon R, Leav B, Miller JM, Das R

medRxiv, 07 Mar 2022

Cited by: 0 articles | PPR: PPR465667

Add to export list Preprint

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials.

Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study

SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.

No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.

Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.

No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial.

Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial.

Risk of COVID-19 after natural infection or vaccination.

Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.

Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS

Risk of COVID-19 after Natural Infection or Vaccination

No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a COVID-19 mRNA-1273 booster vaccine in adults aged 50 years and older: A randomized trial

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial.

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim Analysis

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent Vaccines

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Partnerships & funding